$LXEO

Lexeo Therapeutics, Inc. (LXEO): Submission of Matters to a Vote of Security Holders

Lexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001907108 0001907108 2026-06-25 2026-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25,

Original reporting
Published Jun 29, 2026, 9:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$LXEO
Neutral
high confidence
Mentioned
$LXEO
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LXEONeutralLow
01

Why it matters

Confirms (1) election of Class III directors and (2) ratification of KPMG LLP as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026; no additional corporate actions are described.

02

Market read

This is a governance/administrative disclosure with no new operating or financial catalyst.

03

What to watch

Vote tallies alone rarely change valuation; any meaningful catalyst would typically be tied to new financing, clinical/regulatory updates, or leadership changes, none of which appear here.

Relevance 6/10Novelty 2/10Timing: after-hours/filing date (June 29, 2026) following June 25 annual meeting

Background

The company submitted an SEC Form 8-K under Item 5.07 summarizing matters voted on by stockholders at its virtual 2026 Annual Meeting held June 25, 2026.

Company-level read

Ticker impact

$LXEONeutralHigh confidence
Context

Lexeo Therapeutics filed an 8-K reporting final vote results from its June 25, 2026 annual meeting, including director elections and KPMG ratification.

Expected impact

Low near-term impact; any reaction would be limited to governance/administrative sentiment rather than fundamentals.

Evidence & confidence

The filing discloses election/ratification vote tallies and does not include new financial guidance, deals, litigation, or regulatory actions.

Market effects

No sector read-across; governance vote results are company-specific and administrative.

None indicated.

None indicated.

Counterpoint

Traders could treat director-election outcomes as a signal of board continuity, but the filing provides no qualitative changes or strategic commitments.

Key entities

  • Lexeo Therapeutics, Inc.

    Subject of the 8-K; reported annual meeting vote results for director elections and auditor ratification.

  • KPMG LLP

    Ratified by stockholders as independent registered public accounting firm for FY ending Dec. 31, 2026.

Related articles

$LXEOMed

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics (Nasdaq: LXEO) reported Q2 2026 results and updates. It finalized SUNRISE-FA 2 protocol and SAP for LX2006, with first patient enrolled in June and site activation ongoing. CLARITY-FA enrollment continues. FDA granted RMAT for LX2020. Cash and investments were $234.2M, funding operations into 2028. R&D was $19.0M and net loss $25.9M ($0.30/share).

$LXEOMed

Lexeo Therapeutics, Inc. (LXEO): Results of Operations and Financial Condition

Lexeo Therapeutics, Inc. (LXEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lxeo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data

$LXEOMedAI 9/10

Lexeo's heart gene therapy gets FDA status after interim data

Lexeo Therapeutics (Nasdaq: LXEO) said the FDA granted RMAT designation to its AAV-based gene therapy LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, based on interim data from the HEROIC-PKP2 Phase I/II trial. Lexeo also noted Orphan Drug and Fast Track status. RMAT may support accelerated approval, priority review, and rolling review.

$LXEOMedAI 8/10

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics (Nasdaq: LXEO) said the FDA granted RMAT designation to its investigational AAV-based gene therapy LX2020 for PKP2-associated arrhythmogenic cardiomyopathy. The decision was based on interim data from the ongoing HEROIC-PKP2 Phase I/II trial. Lexeo also noted LX2020 received Orphan Drug and Fast Track designations.